These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 16364615

  • 1. [Ifosfamide induced encephalopathy: 15 observations].
    Dufour C, Grill J, Sabouraud P, Behar C, Munzer M, Motte J, Oberlin O, Paci A, Hartmann O.
    Arch Pediatr; 2006 Feb; 13(2):140-5. PubMed ID: 16364615
    [Abstract] [Full Text] [Related]

  • 2. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.
    Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prové A, Vermorken JB.
    Br J Cancer; 2000 Jan; 82(2):291-4. PubMed ID: 10646879
    [Abstract] [Full Text] [Related]

  • 3. Ifosfamide-induced encephalopathy in patients with uterine sarcoma.
    Liu YL, Tsai SH, Chang FW, Yu MH.
    Taiwan J Obstet Gynecol; 2010 Mar; 49(1):77-80. PubMed ID: 20466298
    [Abstract] [Full Text] [Related]

  • 4. Methylene blue for management of Ifosfamide-induced encephalopathy.
    Patel PN.
    Ann Pharmacother; 2006 Feb; 40(2):299-303. PubMed ID: 16391008
    [Abstract] [Full Text] [Related]

  • 5. Ifosfamide neuropsychiatric toxicity in patients with cancer.
    Alici-Evcimen Y, Breitbart WS.
    Psychooncology; 2007 Oct; 16(10):956-60. PubMed ID: 17278152
    [Abstract] [Full Text] [Related]

  • 6. Role of thiamine in managing ifosfamide-induced encephalopathy.
    Hamadani M, Awan F.
    J Oncol Pharm Pract; 2006 Dec; 12(4):237-9. PubMed ID: 17156595
    [Abstract] [Full Text] [Related]

  • 7. Neurotoxicity during ifosfamide treatment in children.
    Di Cataldo A, Astuto M, Rizzo G, Bertuna G, Russo G, Incorpora G.
    Med Sci Monit; 2009 Jan; 15(1):CS22-5. PubMed ID: 19114973
    [Abstract] [Full Text] [Related]

  • 8. Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.
    Foxall PJ, Singer JM, Hartley JM, Neild GH, Lapsley M, Nicholson JK, Souhami RL.
    Clin Cancer Res; 1997 Sep; 3(9):1507-18. PubMed ID: 9815837
    [Abstract] [Full Text] [Related]

  • 9. Successful treatment of ifosfamide neurotoxicity with dexmedetomidine.
    Bernard PA, McCabe T, Bayliff S, Hayes D.
    J Oncol Pharm Pract; 2010 Dec; 16(4):262-5. PubMed ID: 20118215
    [Abstract] [Full Text] [Related]

  • 10. Ifosfamide encephalopathy and nonconvulsive status epilepticus.
    Primavera A, Audenino D, Cocito L.
    Can J Neurol Sci; 2002 May; 29(2):180-3. PubMed ID: 12035842
    [Abstract] [Full Text] [Related]

  • 11. Ifosfamide encephalopathy and use of methylene blue. A case report of different sequential neurotoxicity.
    Giovanis P, Garna A, Marcante M, Nardi K, Giusto M.
    Tumori; 2009 May; 95(4):545-6. PubMed ID: 19856674
    [Abstract] [Full Text] [Related]

  • 12. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.
    Loebstein R, Atanackovic G, Bishai R, Wolpin J, Khattak S, Hashemi G, Gobrial M, Baruchel S, Ito S, Koren G.
    J Clin Pharmacol; 1999 May; 39(5):454-61. PubMed ID: 10234592
    [Abstract] [Full Text] [Related]

  • 13. Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant.
    Howell JE, Szabatura AH, Hatfield Seung A, Nesbit SA.
    J Oncol Pharm Pract; 2008 Sep; 14(3):157-62. PubMed ID: 18719071
    [Abstract] [Full Text] [Related]

  • 14. Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy.
    Aeschlimann C, Küpfer A, Schefer H, Cerny T.
    Drug Metab Dispos; 1998 Sep; 26(9):883-90. PubMed ID: 9733667
    [Abstract] [Full Text] [Related]

  • 15. Ifosfamide neurotoxicity: an atypical presentation with psychiatric manifestations.
    Kerdudo C, Orbach D, Sarradet JL, Doz F.
    Pediatr Blood Cancer; 2006 Jul; 47(1):100-2. PubMed ID: 16261598
    [Abstract] [Full Text] [Related]

  • 16. Ifosfamide-related encephalopathy in elderly patients : report of five cases and review of the literature.
    Brunello A, Basso U, Rossi E, Stefani M, Ghiotto C, Marino D, Crivellari G, Monfardini S.
    Drugs Aging; 2007 Jul; 24(11):967-73. PubMed ID: 17953463
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity.
    Berrak SG, Pearson M, Berberoğlu S, Ilhan IE, Jaffe N.
    Pediatr Blood Cancer; 2005 Mar; 44(3):215-9. PubMed ID: 15503294
    [Abstract] [Full Text] [Related]

  • 19. Ifosfamide induced encephalopathy in a child with osteosarcoma.
    Sarbay H, Demir ÜF, Yılmaz G, Atay AA, Malbora B.
    J Oncol Pharm Pract; 2021 Jul; 27(5):1302-1306. PubMed ID: 33023384
    [Abstract] [Full Text] [Related]

  • 20. Serotonin Syndrome Complicating Treatment of Ifosfamide Neurotoxicity With Methylene Blue.
    Snyder M, Gangadhara S, Brohl AS, Ludlow S, Nanjappa S.
    Cancer Control; 2017 Jul; 24(5):1073274817729070. PubMed ID: 28975823
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.